138 related articles for article (PubMed ID: 37926491)
1. NLRP12 is a prognostic biomarker and correlated with immune infiltrates in epithelial ovarian cancer.
Ma R; Tang Z; Wang J
J Gene Med; 2024 Jan; 26(1):e3585. PubMed ID: 37926491
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
[TBL] [Abstract][Full Text] [Related]
4. PTTG1IP (PBF) is a prognostic marker and correlates with immune infiltrate in ovarian cancer.
Ma R; Tang Z; Wang J
Am J Transl Res; 2023; 15(1):27-46. PubMed ID: 36777854
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of MMP17 predicts poor clinical outcomes in epithelial ovarian cancer patients.
Xiao C; Wang Y; Cheng Q; Fan Y
Medicine (Baltimore); 2022 Aug; 101(34):e30279. PubMed ID: 36042626
[TBL] [Abstract][Full Text] [Related]
6. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Increased Expression of Annexin A10 (ANXA10) in Serous Epithelial Ovarian Cancer.
Wang J; Zhao S; Wang F; Wang J; Zhang Y
Med Sci Monit; 2019 Jul; 25():5666-5673. PubMed ID: 31363077
[TBL] [Abstract][Full Text] [Related]
8. HTRA3 Is a Prognostic Biomarker and Associated With Immune Infiltrates in Gastric Cancer.
Ji C; Sun LS; Xing F; Niu N; Gao HL; Dai JW; Zhou N; Jiang BC
Front Oncol; 2020; 10():603480. PubMed ID: 33425760
[TBL] [Abstract][Full Text] [Related]
9. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma.
Liao C; Wang A; Ma Y; Liu H
Medicine (Baltimore); 2021 Oct; 100(40):e27473. PubMed ID: 34622876
[TBL] [Abstract][Full Text] [Related]
11. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
12. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer.
Li H; Wu M; Wu Z; Liang J; Wang L; Yang X; Lin Z; Li J
Cancer Immunol Immunother; 2022 Jun; 71(6):1519-1530. PubMed ID: 34724091
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
17. [Expression of lnc-MyD88 and its relationship with the prognosis of patients with epithelial ovarian cancer].
Zhu Y; Huang JM; Zhang GN; Li JM; Huang J
Zhonghua Fu Chan Ke Za Zhi; 2022 Feb; 57(2):117-124. PubMed ID: 35184472
[No Abstract] [Full Text] [Related]
18. Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
Natoli M; Gallon J; Lu H; Amgheib A; Pinato DJ; Mauri FA; Marafioti T; Akarca AU; Ullmo I; Ip J; Aboagye EO; Brown R; Karadimitris A; Ghaem-Maghami S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436485
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
20. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]